Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. - Wikidata - awgldk - TriplyDB

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

http://www.wikidata.org/entity/Q33419558

about

BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice.

P2860

Q37742823-0381963A-86BA-411A-85ED-74F757B7BCA7

P2860

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

http://www.wikidata.org/entity/Q33419558

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@ast

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@en

type

label

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@ast

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@en

prefLabel

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@ast

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@en

P1433

Q33419558-2E104109-1982-4B8B-9F16-EFAF6A0C81D1

P1476

Q33419558-5992484D-9658-4DD7-82F8-C26EBED7CE4D

P2093

Q33419558-68956281-D76B-4326-AFA4-B016FCF2F194

Q33419558-797E2673-2CF2-4888-931D-80D49FFA4B5D

Q33419558-91AE15A9-6D03-43C6-9708-133BE4ABC119

Q33419558-A4887459-F4AC-48D7-B1E3-587441DB7F74

Q33419558-EB72BD97-E0DD-44D5-9462-916F3B54225B

P2860

Q33419558-08628FE4-8DD0-4B0E-9303-198EC407013A

Q33419558-16903E93-6192-4B83-92CE-344EA1122973

Q33419558-17319821-9609-4268-9521-777C86375C5A

Q33419558-18C8DC43-5B62-4C0D-928C-A3ADFBE8734D

Q33419558-2652DB3C-B806-4F59-B8B2-3A34C44C744F

Q33419558-2E9CA5E3-5BBD-4515-8A2C-E702E05BA167

Q33419558-38C54523-A9BE-410B-8A65-505366D6912B

Q33419558-49581033-57B6-493E-BA2A-A4085E230135

Q33419558-5F3E1315-135C-4C54-8996-8FE7669D6201

Q33419558-6EB7CF56-41A2-49FC-980E-231E85645986

P304

Q33419558-60BB57BF-AF18-4F83-A7D8-276886DC26F7

P31

Q33419558-21773FCE-805B-4386-9E3C-5606FEBDADFE

P356

Q33419558-1F05E7C3-4849-4418-88A7-AD86A036924C

P433

Q33419558-3E64F5D1-5EC6-453D-8073-5095DE29448C

P478

Q33419558-4CA2F4DE-EB50-4A98-A9F9-3E8FF5CDB92E

P577

Q33419558-340EEB43-1452-411C-AC09-16D7BE2817AC

P698

Q33419558-F13D53D6-6893-4033-84BA-7DC02FF85BEE

P356

08880018.2014.983624

P1433

Pediatric Hematology and Oncology

P1476

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.

@en

P2093

Araz Marachelian

http://www.w3.org/2001/XMLSchema#string

Hung C Tran

http://www.w3.org/2001/XMLSchema#string

Leo Mascarenhas

http://www.w3.org/2001/XMLSchema#string

Rajkumar Venkatramani

http://www.w3.org/2001/XMLSchema#string

Rima F Jubran

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity

A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study

A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project

Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database

P304

26-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08880018.2014.983624

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25551355

http://www.w3.org/2001/XMLSchema#string